Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
نویسندگان
چکیده
BACKGROUND The impact of patient age on the risks of death or rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement is uncertain. METHODS AND RESULTS Data from 5 major ICD trials were merged: the Multicenter Automatic Defibrillator Implantation Trial I (MADIT-I), the Multicenter UnSustained Tachycardia Trial (MUSTT), the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II), the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Trial (DEFINITE), and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Median age at enrollment was 62 (interquartile range 53-70) years. Compared with their younger counterparts, older patients had a greater burden of comorbid illness. In unadjusted exploratory analyses, ICD recipients were less likely to die than nonrecipients in all age groups: among patients aged <55 years: hazard ratio 0.48, 95% posterior credible interval 0.33 to 0.69; among patients aged 55 to 64 years: hazard ratio 0.69, 95% posterior credible interval 0.53 to 0.90; among patients aged 65 to 74 years: hazard ratio 0.67, 95% posterior credible interval, 0.53 to 0.85; and among patients aged ≥75 years: hazard ratio 0.54, 95% posterior credible interval 0.37 to 0.78. Sample sizes were limited among patients aged ≥75 years. In adjusted Bayesian-Weibull modeling, point estimates indicate ICD efficacy persists but is attenuated with increasing age. There was evidence of an interaction between age and ICD treatment on survival (two-sided posterior tail probability of no interaction <0.01). Using an adjusted Bayesian logistic regression model, there was no evidence of an interaction between age and ICD treatment on rehospitalization (two-sided posterior tail probability of no interaction 0.44). CONCLUSIONS In this analysis, the survival benefit of the ICD exists but is attenuated with increasing age. The latter finding may be because of the higher burden of comorbid illness, competing causes of death, or limited sample size of older patients. There was no evidence that age modifies the association between ICD treatment and rehospitalization.
منابع مشابه
THE EFFECT OF NURSE-PEER-LED SUPPORT INTERVENTION ON QUALITY OF LIFE IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR: A RANDOMIZED CLINICAL TRIAL
Background & Aims: Nowadays, the quality of life and how coping and treatment of patients with an implantable cardiac defibrillator has led to concern and attempts to reduce or eliminate the problems of these patients in the people who provide health care services. This study aimed to determine the effect of nurse-peer-led support intervention on quality of life in patients with an implantable ...
متن کاملImplantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
CONTEXT Implantable cardioverter defibrillator (ICD) therapy is effective in primary and secondary prevention of sudden cardiac death among patients with prior myocardial infarction and depressed ejection fraction. However, conclusive evidence of survival benefit in patients with nonischemic cardiomyopathy (NICM) is still lacking. OBJECTIVE To determine whether ICD therapy reduces all-cause m...
متن کاملProphylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
Strategies to decrease sudden cardiac death in patients with left ventricular systolic dysfunction are evolving. Recent clinical trials have evaluated the role of prophylactic implantable cardioverter-defibrillators (ICDs) in patients with and without additional risk stratifiers. We pooled studies comparing treatment with and without ICDs from published data and presented abstracts, irrespectiv...
متن کاملSurvival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.
IMPORTANCE Randomized clinical trials have shown that implantable cardioverter-defibrillator (ICD) therapy saves lives. Whether the survival of patients who received an ICD in primary prevention clinical trials differs from that of trial-eligible patients receiving a primary prevention ICD in clinical practice is unknown. OBJECTIVE To determine whether trial-eligible patients who received a p...
متن کاملCardiac Resynchronization Therapy in the Autumn of Life.
T o implant or not to implant a primary prevention implantable-cardioverter defibrillator (ICD) in older patients is a question that has challenged clinicians for years. On the one hand, the ICD is a highly effective therapy for the prevention of sudden cardiac death. On the other hand, there are no definitive data regarding the benefit of the ICD in older patients. Indeed, in the pivotal rando...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation. Cardiovascular quality and outcomes
دوره 8 2 شماره
صفحات -
تاریخ انتشار 2015